NDASUBCUTANEOUSSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Drug Shortage Active
OZEMPIC is currently in shortage. Reason: Demand increase. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
OZEMPIC (semaglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2017.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OZEMPIC (semaglutide) is a GLP-1 receptor agonist approved in 2017 for Type 2 Diabetes Mellitus and now indicated for obesity, NAFLD, chronic kidney disease, muscle wasting, mobility disability, and monogenic obesity. It works by mimicking glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. Administered as a subcutaneous injection weekly, it has become a blockbuster therapy across metabolic and cardiovascular indications.
$9.2BPart D
PeakGrowing
12.4 years to LOEPeak commercial phase with massive scale (6.9M annual claims) and sustained high spending; brand teams managing market leadership and supply-demand pressures in a growth-stage market.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
Started Jul 2026
164 enrolled
Muscle WastingObesity & OverweightObesity
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Started Jun 2026
3,000 enrolled
Obesity & Overweight
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Started Jun 2026
150 enrolled
Pediatric ObesityMetabolic and Bariatric SurgerySemaglutide
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Started May 2026
1,000 enrolled
ObesityOverweightDiabetes Mellitus, Type 2
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Started Apr 2026
100 enrolled
Obesity
Worked on OZEMPIC at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.